Status: Not yet recruiting
Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults
The goal of this clinical trial is to learn how people's different genetic makeups affects how their bodies convert the FDA approved drug ARAKODA (tafenoquine) to its active form. Tafenoquine is a drug that is taken to prevent malaria for people traveling to areas where there is malaria. This trial will be in healthy participants age 18-65.
Participants needed: 20
Trial details
Phase: Early Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: State University of New York - Upstate Medical UniversityUpdated: Mar 20, 2026Locations: 1
Eligibility criteria
Age 18-65 at the time of consent, weighing between 132 and 250 pounds [+4]
Women: positive urine pregnancy test at screening or day of dosing [+14]